EF5 to Detect Tumor Hypoxia in Patients With Stage IIB, Stage IIIB, or Stage IVA Cervical Cancer

Completed · Not applicable

Conditions studied: Cervical Cancer

In brief

RATIONALE: Knowing the level of oxygen in tumor tissue may help predict the effectiveness of anticancer therapy. EF5 may be effective in measuring oxygen in tumor tissue and helping to predict the effectiveness of anticancer therapy. PURPOSE: Diagnostic trial to study the effectiveness of EF5 in detecting tumor hypoxia in patients who have stage IIB, stage IIIB, or stage IVA cervical cancer.

Key facts

Study ID

NCT00049231

Run by

Gynecologic Oncology Group

Starts

2003-06-01

Expected to finish

2005-08-01

Last updated by the study team

2013-06-24

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Arkansas Cancer Research Center at University of Arkansas for Medical Sciences — Little Rock, Arkansas, United States
• Colorado Gynecologic Oncology Group P.C. — Denver, Colorado, United States
• Ellis Fischel Cancer Center at University of Missouri - Columbia — Columbia, Missouri, United States
• Oklahoma University Medical Center — Oklahoma City, Oklahoma, United States
• Cancer Care Associates - Midtown Tulsa — Tulsa, Oklahoma, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.